CompletedPhase 1/2

Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue

United States10 participantsStarted 2020-03-12

Plain-language summary

The overarching aim is to assess the role of microglial activation and norepinephrine transporter binding in pathogenesis of MS-related fatigue, using novel Positron Emission Tomography (PET) radiotracers, \[F-18\]PBR06 and \[C-11\]MRB. Specific Aims: Specific Aim 1: To determine the relationship of cerebral microglial activation, as assessed by \[F-18\]PBR06 PET, with MS-related fatigue. Specific Aim 2: To determine the relationship of norepinephrine transporter (NET) binding, as assessed by \[C-11\]MRB PET, with MS-related fatigue. Specific Aim 3: To determine the relationship of microglial activation and NET binding, with grey matter pathology (lesion load and brain atrophy) assessed using 7T MRI, and evaluate their independent contribution in development of MS-related fatigue.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subjects meeting the definition for RRMS or SPMS by International Panel (2017 McDonald) Criteria. * We will recruit patients with RRMS, recently diagnosed in the last 2 years. There will be no disease modifying therapy restrictions for RRMS or SPMS patients. * Male and female subjects age 18 to 60 years. * Patients able to withhold medication that may interfere with C-11\[MRB\] radiotracer uptake for 24 hours before the scan. Exclusion Criteria: * Relapse/Corticosteroid treatment in the past 4 weeks to avoid transient effects on imaging * Individuals with a known alternate neurologic disorder, previous head injury, or substance abuse. * Individuals with bipolar disease and schizophrenia * Concurrent medical conditions that contraindicate study procedures. * Women who are pregnant or nursing. Also, any woman who is seeking to become pregnant or suspects she is pregnant will be excluded from enrollment. * Claustrophobia * Non-MRI compatible implanted devices * Low affinity binders

What they're measuring

Standardized Uptake Value Ratio (SUVR)

Timeframe: Baseline

Area Under the Curve Ratio (AUCR)

Timeframe: Baseline

Trial details

NCT IDNCT04144257

SponsorBrigham and Women's Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-04-13

View on ClinicalTrials.gov More Multiple Sclerosis trials